MCID: ALK016
MIFTS: 49

Alk-Negative Anaplastic Large Cell Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards integrated aliases for Alk-Negative Anaplastic Large Cell Lymphoma:

Name: Alk-Negative Anaplastic Large Cell Lymphoma 60
Anaplastic Large Cell Lymphoma, Alk-Negative 17
Anaplastic Large Cell Lymphoma, Alk Negative 74
Anaplastic Large Cell Lymphoma, Alk-Positive 74
Alk- Anaplastic Large Cell Lymphoma 60
Alk- Alcl 60

Characteristics:

Orphanet epidemiological data:

60
alk-negative anaplastic large cell lymphoma
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

ICD10 34 C84.6 C84.7
ICD10 via Orphanet 35 C84.7
UMLS via Orphanet 75 C1332078
Orphanet 60 ORPHA300903

Summaries for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards based summary : Alk-Negative Anaplastic Large Cell Lymphoma, also known as anaplastic large cell lymphoma, alk-negative, is related to alk-positive anaplastic large cell lymphoma and lymphoma. An important gene associated with Alk-Negative Anaplastic Large Cell Lymphoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Vincristine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include t cells, nk cells and breast, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Alk-Negative Anaplastic Large Cell Lymphoma

Diseases in the Alk-Positive Anaplastic Large Cell Lymphoma family:

Alk-Negative Anaplastic Large Cell Lymphoma

Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Related Disease Score Top Affiliating Genes
1 alk-positive anaplastic large cell lymphoma 32.9 ALK STAT3
2 lymphoma 31.6 ALK BAX BCL2 MYC
3 peripheral t-cell lymphoma 30.7 ALK CCR4 CXCR3
4 anaplastic large cell lymphoma 11.1
5 lymphomatoid papulosis 10.4
6 high grade b-cell lymphoma with myc and/ or bcl2 and/or bcl6 rearrangement 10.3 BCL2 MYC
7 diffuse large b-cell lymphoma of the central nervous system 10.3 BCL2 MYC
8 kashin-beck disease 10.2 BAX BCL2
9 myelodysplastic syndrome 10.2
10 sarcoma 10.2
11 patulous eustachian tube 10.2
12 capillary leak syndrome 10.2
13 ichthyosis 10.2
14 hypereosinophilic syndrome 10.2
15 ichthyosis, acquired 10.2
16 soft tissue sarcoma 10.2
17 systemic capillary leak syndrome 10.2
18 rapidly involuting congenital hemangioma 10.2
19 malignant teratoma 10.1 BAX BCL2
20 primary mediastinal large b-cell lymphoma 10.1 CD274 MYC
21 suppressor of tumorigenicity 3 10.1 BAX BCL2 MYC
22 lymphoma, hodgkin, classic 10.1
23 asthma 10.1
24 hematopoietic stem cell transplantation 10.1
25 leukemia 10.1
26 pemphigus foliaceus 10.1
27 lymphocytic leukemia 10.1
28 syphilis 10.1
29 cytokine deficiency 10.1
30 differentiated thyroid carcinoma 10.1 ALK BCL2 CD274 DPP4
31 oral lichen planus 10.1 BAX CXCR3 TP63
32 myasthenic syndrome, congenital, 14 10.0 CD274 MYC
33 focal cortical dysplasia, type ii 10.0 BAX BCL2 BCL2L1
34 primary central nervous system lymphoma 10.0 BCL2 CD274
35 apical myocardial infarction 10.0 BCL2L1 STAT3
36 hematologic cancer 9.9 ADA ALK BAX MYC
37 respiratory system cancer 9.9 ALK CD274 MYC STAT3
38 leukocyte disease 9.9 BAX BCL2L1 MYC
39 breast adenocarcinoma 9.8 BAX BCL2L1 MYC
40 acute promyelocytic leukemia 9.8 BAX BCL2 MYC STAT3
41 mycosis fungoides 9.8 CCR4 CXCR3 DPP4 STAT3
42 b-cell lymphomas 9.8 BAX BCL2 BCL2L1 MYC
43 burkitt lymphoma 9.7 BAX BCL2 BCL2L1 MYC
44 lymphoma, non-hodgkin, familial 9.7 ALK BAX BCL2 BCL2L1 MYC
45 large intestine cancer 9.6 BCL2L1 CD274 MYC STAT3
46 leukemia, chronic lymphocytic 9.6 BAX BCL2 BCL2L1 CXCR3 STAT3
47 nasopharyngeal carcinoma 9.6 BCL2 BCL2L1 MYC STAT3
48 myeloma, multiple 9.6 BCL2L1 MYC PMAIP1 STAT3
49 cervical cancer 9.5 BAX BCL2 MYC STAT3 TP63
50 mantle cell lymphoma 9.5 BCL2 BCL2L1 MYC PMAIP1 STAT3

Graphical network of the top 20 diseases related to Alk-Negative Anaplastic Large Cell Lymphoma:



Diseases related to Alk-Negative Anaplastic Large Cell Lymphoma

Symptoms & Phenotypes for Alk-Negative Anaplastic Large Cell Lymphoma

GenomeRNAi Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.32 BAX BCL2 BCL2L1 DUSP22
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.32 BAX BCL2 BCL2L1 DUSP22 MYC TP63

MGI Mouse Phenotypes related to Alk-Negative Anaplastic Large Cell Lymphoma:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.21 ADA ALK BAX BCL2 BCL2L1 CD274
2 growth/size/body region MP:0005378 10.18 ADA ADARB1 ALK BAX BCL2 BCL2L1
3 endocrine/exocrine gland MP:0005379 10.15 ADA ALK BAX BCL2 BCL2L1 DPP4
4 hematopoietic system MP:0005397 10.11 ADA BAX BCL2 BCL2L1 CCR4 CD274
5 immune system MP:0005387 10.1 ADA BAX BCL2 BCL2L1 CCR4 CD274
6 mortality/aging MP:0010768 10.06 ADA ADARB1 ALK BAX BCL2 BCL2L1
7 integument MP:0010771 9.91 ALK BCL2 BCL2L1 CD274 MYC STAT3
8 neoplasm MP:0002006 9.81 ALK BAX BCL2 BCL2L1 CXCR3 FRK
9 muscle MP:0005369 9.8 ADA ADARB1 BAX BCL2 MYC STAT3
10 reproductive system MP:0005389 9.56 ADA ALK BAX BCL2 BCL2L1 MYC
11 respiratory system MP:0005388 9.17 ADA ALK BAX CCR4 CXCR3 STAT3

Drugs & Therapeutics for Alk-Negative Anaplastic Large Cell Lymphoma

Drugs for Alk-Negative Anaplastic Large Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
2
Ifosfamide Approved Phase 4,Phase 2 3778-73-2 3690
3
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 53-03-2 5865
4
Epirubicin Approved Phase 4 56420-45-2 41867
5
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
6
Cisplatin Approved Phase 4 15663-27-1 441203 84093 2767
7
Etoposide Approved Phase 4,Phase 2,Phase 1 33419-42-0 36462
8
Gemcitabine Approved Phase 4 95058-81-4 60750
9
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2 1177-87-3
10
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2 50-02-2 5743
11
Crizotinib Approved Phase 4,Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
12
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 1 23214-92-8 31703
13
Methotrexate Approved Phase 4,Phase 2 1959-05-2, 59-05-2 126941
14
Mechlorethamine Approved, Investigational Phase 4,Phase 2 51-75-2 4033
15
leucovorin Approved Phase 4,Phase 2 58-05-9 6006 143
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2 59-30-3 6037
17
Doxil Approved June 1999 Phase 4,Phase 2,Phase 1 31703
18
Pirarubicin Investigational Phase 4 72496-41-4
19
Isophosphamide mustard Phase 4,Phase 2 0
20 Anti-Bacterial Agents Phase 4,Phase 2,Phase 1
21 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 1
22 Antineoplastic Agents, Alkylating Phase 4,Phase 2,Phase 1
23 Etoposide phosphate Phase 4,Phase 2,Phase 1
24 Hormones Phase 4,Phase 2,Phase 1
25 BB 1101 Phase 4,Phase 2
26 Immunosuppressive Agents Phase 4,Phase 2,Phase 1
27 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 1
28 Hormone Antagonists Phase 4,Phase 2,Phase 1
29 Immunologic Factors Phase 4,Phase 1,Phase 2
30 Topoisomerase Inhibitors Phase 4,Phase 2,Phase 1
31 Alkylating Agents Phase 4,Phase 2,Phase 1
32 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 1
33 Antimitotic Agents Phase 4,Phase 2,Phase 1
34 Antineoplastic Agents, Phytogenic Phase 4,Phase 2,Phase 1
35 Antirheumatic Agents Phase 4,Phase 2,Phase 1
36 glucocorticoids Phase 4,Phase 2,Phase 1
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 1
38 Protein Kinase Inhibitors Phase 4,Phase 1,Phase 2
39 Dermatologic Agents Phase 4,Phase 2,Phase 1
40 Antimetabolites Phase 4,Phase 2
41 Vitamin B Complex Phase 4,Phase 2
42 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
43 Antimetabolites, Antineoplastic Phase 4,Phase 2
44 Folate Phase 4,Phase 2
45 Vitamin B9 Phase 4,Phase 2
46 Folic Acid Antagonists Phase 4,Phase 2
47
Ceritinib Approved Phase 1, Phase 2 1032900-25-6
48
Daunorubicin Approved Phase 2 20830-81-3 30323
49
alemtuzumab Approved, Investigational Phase 2 216503-57-0
50
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326

Interventional clinical trials:

(show all 13)
# Name Status NCT ID Phase Drugs
1 CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL Unknown status NCT02533700 Phase 4 CEOP/IVE/GDP chemotherapy regimen;CEOP chemotherapy regimen for 6 cycles
2 Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL Recruiting NCT03707847 Phase 4 Crizotinib;Etoposide Capsule
3 CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma Active, not recruiting NCT01746992 Phase 4 Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4 A Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms Recruiting NCT03493451 Phase 2 BGB A317
5 Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT03719898 Phase 2 Brigatinib
6 Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Recruiting NCT02729961 Phase 1, Phase 2 Brentuximab Vedotin;Ceritinib
7 A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma Recruiting NCT03505554 Phase 2 Lorlatinib
8 Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Recruiting NCT02419287 Phase 2 crizotinib
9 Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma Recruiting NCT03113500 Phase 2 Brentuximab Vedotin;Cyclophosphamide;Doxorubicin;Etoposide;Prednisone
10 Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas Active, not recruiting NCT00069238 Phase 2 EPOCH
11 Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Active, not recruiting NCT02561273 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Lenalidomide;Prednisone;Vincristine Sulfate
12 Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Suspended NCT01979536 Phase 2 Brentuximab Vedotin;Crizotinib;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
13 Prospective Study of the Prognostic Value of New Markers in Adults With ALK-positive Large Anaplastic Lymphoma Recruiting NCT03603847

Search NIH Clinical Center for Alk-Negative Anaplastic Large Cell Lymphoma

Genetic Tests for Alk-Negative Anaplastic Large Cell Lymphoma

Anatomical Context for Alk-Negative Anaplastic Large Cell Lymphoma

MalaCards organs/tissues related to Alk-Negative Anaplastic Large Cell Lymphoma:

42
T Cells, Nk Cells, Breast, Bone, Lymph Node, Bone Marrow, Small Intestine

Publications for Alk-Negative Anaplastic Large Cell Lymphoma

Articles related to Alk-Negative Anaplastic Large Cell Lymphoma:

(show top 50) (show all 58)
# Title Authors Year
1
A Rare Case of Neutrophil-Rich, ALK-Negative Anaplastic Large Cell Lymphoma in the Lung Mimicking a Pulmonary Abscess on 18F-FDG PET/CT. ( 30562196 )
2019
2
ALK-negative anaplastic large cell lymphoma arising in the thrombus of an aortic prosthesis preceeded by clonally related lymphomatoid papulosis. ( 30685783 )
2019
3
Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. ( 30873584 )
2019
4
The Long Non-Coding RNA MIR503HG Enhances Proliferation of Human ALK-Negative Anaplastic Large-Cell Lymphoma. ( 29758012 )
2018
5
Targetable fusions of the FRK tyrosine kinase in ALK-negative anaplastic large cell lymphoma. ( 29026208 )
2018
6
FOXP3-positive T-cell lymphomas in non-HTLV1 carriers include ALK-negative anaplastic large cell lymphoma: expanding the Spectrum of T-cell lymphomas with regulatory phenotype. ( 29898383 )
2018
7
Prognostic factors of ALK-negative anaplastic large-cell lymphoma: a single-institution experience. ( 29359238 )
2018
8
Acquired ichthyosis as a paraneoplastic feature of ALK-negative anaplastic large cell lymphoma. ( 30407628 )
2018
9
ALK-Negative Anaplastic Large Cell Lymphoma Presenting as an Extranodal Soft-Tissue Mass With an Unusual Alveolar Growth Pattern: A Diagnostic Challenge. ( 28381153 )
2017
10
DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. ( 28522440 )
2017
11
PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. ( 28344319 )
2017
12
Indolent ALK-Negative Anaplastic Large Cell Lymphoma, DUSP22 Rearranged, with an Unusual Immunophenotype in an HIV Patient. ( 28042680 )
2017
13
Secondary CNS involvement of ALK-negative anaplastic large cell lymphoma. ( 28370436 )
2017
14
ALK-negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. ( 28139895 )
2017
15
The masquerading presentation of a systemic anaplastic large cell lymphoma, ALK positive: a case report and review of the literature. ( 28441913 )
2017
16
Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin. ( 26809026 )
2016
17
Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience. ( 27209536 )
2016
18
ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. ( 27460479 )
2016
19
ALK-negative anaplastic large cell lymphoma with loss of CD30 expression during treatment with brentuximab vedotin. ( 27263791 )
2016
20
Primary rare anaplastic large cell lymphoma, ALK positive in small intestine: case report and review of the literature. ( 27612448 )
2016
21
ALK-negative anaplastic large-cell lymphoma. ( 26769771 )
2016
22
ALK-negative anaplastic large cell lymphoma is sensitive to bortezomib through Noxa upregulation and release of Bax from Bcl-2. ( 25975837 )
2015
23
Primary pancreatic ALK negative anaplastic large cell lymphoma. ( 25474521 )
2015
24
A case of ALK negative anaplastic large cell lymphoma with leukaemic manifestation, transformed from CD4 positive T-cell large granular lymphocytic leukaemia. ( 25474523 )
2015
25
Progress in the identification of subgroups in ALK-negative anaplastic large-cell lymphoma. ( 26223379 )
2015
26
Axillary Lymphadenopathy: An Outstanding Presentation for Breast Implant-Associated ALK-Negative Anaplastic Large Cell Lymphoma. ( 25829459 )
2015
27
PAX5-expressing ALK-negative anaplastic large cell lymphoma with extensive extranodal and nodal involvement. ( 26187868 )
2015
28
Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 24976005 )
2014
29
ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. ( 24894770 )
2014
30
Flow cytometry of ALK-negative anaplastic large cell lymphoma of breast implant-associated effusion and capsular tissue. ( 25044944 )
2014
31
Breast implant-associated ALK-negative anaplastic large cell lymphoma: a case report and discussion of possible pathogenesis. ( 23923082 )
2013
32
Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity. ( 23480896 )
2013
33
Composite ALK-negative anaplastic large cell lymphoma and small lymphocytic lymphoma involving the right inguinal lymph node. ( 24169448 )
2013
34
Refractory Case of ALK-Negative Anaplastic Large-Cell Lymphoma with PAX-5 Expression and T-Cell Receptor-I^ Gene Rearrangement. ( 24369229 )
2013
35
ALK-negative anaplastic large cell lymphoma primarily involving the bronchus: a case report and literature review. ( 24427373 )
2013
36
Lymphohistiocytic and small cell pattern of anaplastic large cell lymphoma, ALK positive, arising in an 86-year-old woman. ( 23692425 )
2013
37
Two cases of CD30+, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with oral manifestations. ( 22940020 )
2013
38
Systemic Capillary Leak Syndrome as an Initial Presentation of ALK-Negative Anaplastic Large Cell Lymphoma. ( 22953081 )
2012
39
Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. ( 22740451 )
2012
40
High-risk ALK negative anaplastic large-cell lymphoma presenting with hypereosinophilic syndrome in a 2.5-year-old child. ( 23013405 )
2012
41
Anaplastic large cell lymphoma, ALK-positive. ( 22440390 )
2012
42
Leukemic presentation of ALK-negative anaplastic large cell lymphoma in a patient with myelodysplastic syndrome. ( 22246491 )
2012
43
Pathobiology of ALK-negative anaplastic large cell lymphoma. ( 22053281 )
2011
44
ALK-negative anaplastic large cell lymphoma mimicking a soft tissue sarcoma. ( 22090705 )
2011
45
Rapid fatal pulmonary complications in a Chinese patient after bortezomib treatment for ALK-negative anaplastic large-cell lymphoma. ( 20371451 )
2010
46
Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma. ( 20217288 )
2010
47
Secondary ALK negative anaplastic large cell lymphoma in a patient with lymphomatoid papulosis of 40 years duration. ( 20644462 )
2010
48
ALK-negative anaplastic large cell lymphoma with extensive peripheral blood and bone marrow involvements manifested as "leukemic phase". ( 19695703 )
2010
49
ALK-negative anaplastic large cell lymphoma in leukemic phase with near-pentaploidy. ( 20846102 )
2010
50
A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. ( 20976631 )
2010

Variations for Alk-Negative Anaplastic Large Cell Lymphoma

Expression for Alk-Negative Anaplastic Large Cell Lymphoma

Search GEO for disease gene expression data for Alk-Negative Anaplastic Large Cell Lymphoma.

Pathways for Alk-Negative Anaplastic Large Cell Lymphoma

Pathways related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 55)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 ALK BAX BCL2 BCL2L1 CCR4 CXCR3
2
Show member pathways
13.63 ALK BAX BCL2 BCL2L1 CCR4 CXCR3
3
Show member pathways
12.93 BAX BCL2 BCL2L1 CCR4 MYC STAT3
4
Show member pathways
12.81 BAX BCL2 BCL2L1 MYC PMAIP1 STAT3
5
Show member pathways
12.72 BAX BCL2 BCL2L1 MYC PMAIP1 TP63
6
Show member pathways
12.66 ALK BAX BCL2 BCL2L1 STAT3
7
Show member pathways
12.65 BAX BCL2 BCL2L1 PMAIP1 STAT3
8 12.59 ALK BAX BCL2 BCL2L1 MYC PMAIP1
9
Show member pathways
12.55 BCL2 BCL2L1 MYC STAT3
10
Show member pathways
12.55 BAX BCL2 BCL2L1 MYC STAT3
11
Show member pathways
12.52 BAX BCL2 BCL2L1 STAT3
12 12.47 BCL2 MYC STAT3 TP63
13
Show member pathways
12.42 BAX BCL2 BCL2L1 MYC STAT3
14
Show member pathways
12.36 BCL2 BCL2L1 MYC STAT3
15
Show member pathways
12.36 BAX BCL2L1 MYC STAT3
16 12.27 BAX CCR4 PMAIP1 STAT3
17
Show member pathways
12.24 BAX BCL2 BCL2L1 MYC PMAIP1
18
Show member pathways
12.17 BAX BCL2 BCL2L1 MYC
19 12.15 BAX BCL2L1 MYC STAT3
20 12.11 BAX BCL2 BCL2L1 MYC
21
Show member pathways
12.03 BAX BCL2 MYC STAT3
22 12.03 BAX BCL2 BCL2L1 MYC PMAIP1
23
Show member pathways
12.02 BCL2 MYC STAT3
24 12.02 BAX BCL2 PMAIP1 TP63
25 12.01 MYC STAT3 TP63
26
Show member pathways
11.94 BAX BCL2 BCL2L1
27 11.94 BAX BCL2 MYC PMAIP1
28 11.92 BCL2 BCL2L1 MYC STAT3
29
Show member pathways
11.9 BAX PMAIP1 TP63
30 11.87 BAX BCL2 STAT3
31
Show member pathways
11.8 BCL2 BCL2L1 MYC STAT3
32 11.77 BAX MYC PMAIP1
33 11.76 BAX BCL2 BCL2L1 MYC
34 11.74 ADA BCL2 MYC
35
Show member pathways
11.68 BAX BCL2 BCL2L1 PMAIP1
36
Show member pathways
11.67 BCL2 BCL2L1 MYC
37
Show member pathways
11.65 BAX BCL2 BCL2L1 PMAIP1 TP63
38 11.6 BAX BCL2 BCL2L1 PMAIP1
39 11.53 BCL2L1 MYC STAT3
40 11.53 BAX BCL2 BCL2L1
41
Show member pathways
11.48 BCL2L1 MYC STAT3
42 11.47 BAX BCL2 MYC
43 11.44 BAX BCL2 MYC
44 11.36 BAX BCL2L1 PMAIP1
45 11.33 BCL2L1 MYC STAT3
46 11.27 BAX BCL2 BCL2L1
47
Show member pathways
11.26 BAX BCL2 BCL2L1 PMAIP1
48
Show member pathways
11.2 BCL2 BCL2L1 MYC STAT3
49 11.17 BAX BCL2 MYC
50 11.06 BCL2 BCL2L1

GO Terms for Alk-Negative Anaplastic Large Cell Lymphoma

Cellular components related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.56 ADA CCR4 CD274 CXCR3
2 pore complex GO:0046930 9.16 BAX BCL2
3 Bcl-2 family protein complex GO:0097136 8.96 BAX BCL2L1
4 mitochondrial outer membrane GO:0005741 8.92 BAX BCL2 BCL2L1 PMAIP1

Biological processes related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.97 ADA BCL2 BCL2L1 MYC STAT3
2 response to drug GO:0042493 9.96 ADA BCL2 MYC STAT3
3 cytokine-mediated signaling pathway GO:0019221 9.95 BCL2 BCL2L1 MYC STAT3
4 regulation of cell cycle GO:0051726 9.89 ADARB1 BAX BCL2 STAT3
5 negative regulation of cell migration GO:0030336 9.85 ADARB1 BCL2 DUSP22
6 cellular response to hypoxia GO:0071456 9.85 BCL2 MYC PMAIP1
7 regulation of apoptotic process GO:0042981 9.85 ALK BAX BCL2 BCL2L1 PMAIP1 TP63
8 male gonad development GO:0008584 9.83 BAX BCL2 BCL2L1
9 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.77 BAX BCL2 BCL2L1
10 response to radiation GO:0009314 9.75 BCL2 BCL2L1 CCR4
11 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.73 BAX BCL2 BCL2L1
12 response to cytokine GO:0034097 9.73 BCL2 BCL2L1 CD274 STAT3
13 response to gamma radiation GO:0010332 9.72 BAX BCL2 MYC
14 regulation of mitochondrial membrane potential GO:0051881 9.71 BAX BCL2 BCL2L1
15 B cell homeostasis GO:0001782 9.68 BAX BCL2
16 homeostasis of number of cells GO:0048872 9.68 BAX CCR4
17 mitochondrion morphogenesis GO:0070584 9.68 BAX BCL2L1
18 positive regulation of protein oligomerization GO:0032461 9.67 BAX PMAIP1
19 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.67 BCL2 PMAIP1 TP63
20 endoplasmic reticulum calcium ion homeostasis GO:0032469 9.66 BAX BCL2
21 apoptotic mitochondrial changes GO:0008637 9.65 BAX BCL2 BCL2L1
22 regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043281 9.64 BAX TP63
23 regulation of protein heterodimerization activity GO:0043497 9.63 BAX BCL2
24 protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:0001844 9.62 BAX PMAIP1
25 regulation of protein homodimerization activity GO:0043496 9.62 BAX BCL2
26 neuron apoptotic process GO:0051402 9.62 BAX BCL2 BCL2L1 TP63
27 leukocyte homeostasis GO:0001776 9.61 BAX BCL2
28 regulation of cell-cell adhesion mediated by integrin GO:0033632 9.58 ADA DPP4
29 ovarian follicle development GO:0001541 9.58 BAX BCL2 BCL2L1
30 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.56 BAX BCL2 BCL2L1 PMAIP1
31 positive regulation of developmental pigmentation GO:0048087 9.52 BAX BCL2
32 regulation of nitrogen utilization GO:0006808 9.51 BAX BCL2
33 release of cytochrome c from mitochondria GO:0001836 9.46 BAX BCL2 BCL2L1 PMAIP1
34 positive regulation of smooth muscle cell migration GO:0014911 9.37 BCL2
35 hypothalamus development GO:0021854 9.35 BAX
36 positive regulation of ATP biosynthetic process GO:2001171 9.34 STAT3
37 regulation of mitochondrial membrane permeability GO:0046902 9.26 BCL2 BCL2L1 PMAIP1 STAT3
38 cell proliferation GO:0008283 9.17 ALK BAX BCL2 BCL2L1 DUSP22 STAT3
39 positive regulation of cell proliferation GO:0008284 10.03 BCL2 BCL2L1 DPP4 MYC STAT3
40 negative regulation of cell proliferation GO:0008285 10.01 ADARB1 BAX BCL2 FRK STAT3
41 apoptotic process GO:0006915 10 BAX BCL2 BCL2L1 CXCR3 DUSP22 PMAIP1

Molecular functions related to Alk-Negative Anaplastic Large Cell Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.5 ALK BAX BCL2 BCL2L1 DPP4 STAT3
2 chemokine receptor activity GO:0004950 9.26 CCR4 CXCR3
3 adenosine deaminase activity GO:0004000 9.16 ADA ADARB1
4 BH3 domain binding GO:0051434 8.8 BAX BCL2 BCL2L1

Sources for Alk-Negative Anaplastic Large Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....